AN2 Therapeutics (ANTX) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 254.8% versus a loss of 71.2%. AN2 Therapeutics is the larger company by market cap ($166.0 million vs $161.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | NBP |
|---|---|---|
| Share price | $4.40 | $1.40 |
| Market cap | $166.04M | $161.82M |
| 1-day change | -5.98% | +1.82% |
| YTD return | +285.96% | -64.95% |
| 1-year return | +254.84% | -71.24% |
| 5-year return | — | -97.88% |
| EPS (TTM) | $-1.05 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $6.79 |
| 52-week low | $1.00 | $1.31 |
| Distance from 52-week high | -38.80% | -79.46% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.55% | +545.16% |
| Average volume | 237.87K | 380.06K |
| Shares outstanding | 37.74M | 116.00M |
| Employees | 21 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed NBP by 326.1 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
ANTX vs NBP FAQ
Which is bigger, AN2 Therapeutics or NovaBridge Biosciences?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $166.04M compared with $161.82M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, ANTX or NBP?
ANTX returned +254.84% over the past 12 months, compared with -71.24% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.